Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiac Arrhythmia Management during COVID-19 Pandemic
Author(s): Niraj Varma , Oussama M Wazni , Daniel Cantillon Start date: May 11, 2020

COVID-19
image
Added: 3 years ago
In this series, Mikhail Kosiborod and Hertzel Gerstein discuss the effects of Covid-19 and metabolic disease, early treatment with metabolic therapies and the Phase III DARE-19 Trial looking at dapagliflozin in Covid-19 patients. Recorded remotely from Hamilton and Kansas City, 2020. View more

COVID-19

Prevention & Chronic Conditions
ESC 2020: Thromboembolic Event and Bleeding Risk in COVID-19
Author(s): Yutao Guo Added: 3 years ago
Dr Yutao Guo (Chinese PLA General Hospital, Beijing, CN) discusses thromboembolic events and bleeding risk in COVID-19 patients. Questions: 1. What is the background of your study? 2. What were the methods of this study? 3. What were your results? 4. What conclusions can be made? 5. What patients will benefit most from these findings? 6. What are the next steps? 7. How should these… View more

COVID-19
European Society of Cardiology Highlights: Late-breaking Trials – COVID-19
Author(s): Maki Komiyama , Koji Hasegawa Added: 2 years ago

Anticoagulation

COVID-19
Gestion de l’Arythmie Cardiaque Pendant la Pandémie du COVID-19
Author(s): Christophe Leclercq , Ruben Casado , Jan Steffel Start date: May 13, 2020

COVID-19
Cardiac Involvement Due to COVID-19
Author(s): Valentina O Puntmann , Anastasia Shchendrygina , Carlos Rodriguez Bolanos , et al Added: 6 months ago

Imaging & Diagnostics

COVID-19
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID
Author(s): Renato D Lopes Added: 1 year ago
ESC Congress 22 — Prof Renato Lopes (Duke University Medical Center, US) talks about the data from the APOLLO trial (NCT04746339). This randomized, double-blinded trial compared a DOAC, Apixaban 2.5 MG twice daily with placebo for 30 days. The trial assessed this intervention in outpatients with symptomatic SARS-CoV2 infection and risk factors for thrombosis. The primary outcome measure focused… View more

Anticoagulation

Vascular Disease and Surgery
Innovations in implantable cardiac monitoring in the COVID-19 pandemic and beyond
Author(s): Jan Steffel , , Start date: Sep 23, 2021

Electrophysiology & Arrhythmia

Digital Health
ESC 22: COVID-PACT: Antithrombotic Therapy in Critically Ill COVID-19 Pts
Author(s): David Berg Added: 1 year ago
ESC Congress 22 — Dr David Berg (Brigham and Women's Hospital, US) shares key results from the TIMI Study Group's COVID-PACT trial (NCT04409834). This multicenter, randomized-controlled trial assessed efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events. The study… View more

Anticoagulation

Vascular Disease and Surgery
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19
Author(s): Sanjit Jolly Added: 1 year ago
ESC Congress 22 — Dr Sanjit Jolly (Population Health Research Institute, CA) talk about the Anti-Coronavirus Therapies (ACT) trials (NCT04324463). The data is from two parallel trials assessing the effects of interventions in inpatients and outpatients with COVID-19. The ACT trials are testing whether anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin in… View more

Anticoagulation

Vascular Disease and Surgery